# Phase 3 Diabetes Mellitus, Type 2 trials: 80 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 80 trials in phase 3 for Diabetes Mellitus, Type 2 that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Diabetes Mellitus, Type 2 trials: 80 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/diabetes-mellitus-type-2

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 80
- Recruiting or not yet: 80
- Read on: November 19, 2026

## Trials

The 25 newest of 80, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07934225 | Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes | Fayoum University | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2, Insulin Resistance Syndrome | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934225) |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 12, 2026 | NCT07931547 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931547) |
| November 12, 2026 | NCT07931495 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931495) |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922330) |
| November 6, 2026 | NCT07920939 | Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Type 2 Diabetes | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920939) |
| November 4, 2026 | NCT07915609 | A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2 | 756 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915609) |
| November 3, 2026 | NCT07913061 | A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913061) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 22, 2026 | NCT07889648 | A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar... | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Type 2 Diabetes Mellitus | 948 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889648) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 8, 2026 | NCT07866066 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Amgen | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866066) |
| September 28, 2026 | NCT07843485 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843485) |
| September 14, 2026 | NCT07817251 | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Novo Nordisk A/S | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817251) |
| September 11, 2026 | NCT07816198 | A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy | Addpharma Inc. | Phase 3 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM) | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816198) |
| September 1, 2026 | NCT07797335 | AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People... | Novo Nordisk A/S | Phase 3 | Recruiting | Type 2 Diabetes, Cardiovascular Risk | 1,778 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797335) |
| August 25, 2026 | NCT07784270 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | AstraZeneca | Phase 3 | Recruiting | Obesity or Overweight, Diabetes Mellitus, Type 2 | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784270) |
| August 20, 2026 | NCT07776509 | A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With... | AstraZeneca | Phase 3 | Recruiting | Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2 | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776509) |
| August 20, 2026 | NCT07775404 | A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2... | AstraZeneca | Phase 3 | Recruiting | Obesity, Overweight | 351 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775404) |
| August 10, 2026 | NCT07754461 | A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Boehringer Ingelheim | Phase 3 | Recruiting | Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754461) |
| August 4, 2026 | NCT07743983 | A Study of BGM0504 in Early T2DM With Obesity | BrightGene Bio-Medical Technology Co., Ltd. | Phase 3 | Recruiting | Type 2 Diabetes (T2DM) | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743983) |
| August 3, 2026 | NCT07743450 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Ascletis Pharma (China) Co., Limited | Phase 3 | Recruiting | Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus | 1,560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743450) |
| July 6, 2026 | NCT07684144 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Amgen | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684144) |
| June 26, 2026 | NCT07670416 | A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670416) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 9 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 8 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 6 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 4 |
| [EMS](https://specstream.ai/data/clinical-trials/company/ems) | 4 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 4 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 2 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 2 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 2 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 2 |
| [Celltrion](https://specstream.ai/data/clinical-trials/company/celltrion) | 1 |
| The George Institute | 1 |
| Oramed, Ltd. | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| [Shandong New Time Pharmaceutical Co., LTD](https://specstream.ai/data/clinical-trials/company/shandong-new-time-pharmaceutical-co-ltd) | 1 |
| [Hanlim Pharm. Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hanlim-pharm-co-ltd) | 1 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Montreal Heart Institute | 1 |
| Unity Health Toronto | 1 |
| [Hanmi Pharmaceutical Company Limited](https://specstream.ai/data/clinical-trials/company/hanmi-pharmaceutical-company-limited) | 1 |
| [Fujian Shengdi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd) | 1 |
| CMG Pharmaceutical Co. Ltd | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 35 |
| United States | 34 |
| South Korea | 21 |
| Brazil | 18 |
| Japan | 18 |
| Canada | 17 |
| Poland | 16 |
| Argentina | 15 |
| Germany | 15 |
| India | 15 |
| Spain | 14 |
| United Kingdom | 13 |
| Mexico | 12 |
| Taiwan | 12 |
| Australia | 11 |
| Czechia | 11 |
| Italy | 10 |
| Puerto Rico | 10 |
| Turkey (Türkiye) | 10 |
| Hungary | 9 |
| Bulgaria | 8 |
| Greece | 8 |
| Slovakia | 8 |
| Denmark | 7 |
| France | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Diagnostic imaging centers in the United States](https://specstream.ai/data/businesses/diagnostic-imaging-centers/united-states)
- [Cajun and Creole restaurants in the United States](https://specstream.ai/data/businesses/cajun-and-creole-restaurants/united-states)
- [B2B energy and utility companies in the United States](https://specstream.ai/data/businesses/b2b-energy-and-utility-companies/united-states)
- [Water utilities in the United States](https://specstream.ai/data/businesses/water-utilities/united-states)
